SCHEMBL6455626

SCHEMBL6455626

COc1cccc(C(=O)N[C@H]2CC[C@@H](N)CC2)c1

nearest known ligand 0.69

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
SMYD3 Q9H7B4 7/20 0.69
ALDH1A1 P00352 2/20 0.63
TSHR P16473 1/20 0.63
NPC1 O15118 2/20 0.63
GRM5 P41594 1/20 0.61
RAB9A P51151 2/20 0.58
SMN1; SMN2 Q16637 2/20 0.58
LMNA P02545 2/20 0.58
GAA P10253 1/20 0.58
MCHR1 Q99705 3/20 0.57
PKM P14618 1/20 0.56
HPGD P15428 1/20 0.56
PRSS1 P07477 1/20 0.56
PRSS2 P07478 1/20 0.56
PRSS3 P35030 1/20 0.56
ST14 Q9Y5Y6 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6455623 1.00 SMYD3 (0.69) SMYD3ALDH1A1TSHRNPC1GRM5
SCHEMBL2468483 0.93 NPC1 (0.71) SMYD3ALDH1A1TSHRNPC1GRM5
SCHEMBL1667825 0.87 RAB9A (0.73) ALDH1A1TSHRNPC1GRM5RAB9A
SCHEMBL11241115 0.86 RAB9A (0.75) ALDH1A1TSHRNPC1GRM5RAB9A
SCHEMBL21489786 0.85 SMYD3 (0.72) SMYD3PRSS1PRSS2PRSS3ST14
SCHEMBL19701334 0.85 SMYD3 (0.72) SMYD3PRSS1PRSS2PRSS3ST14
SCHEMBL3663354 0.84 ALDH1A1 (0.61) SMYD3ALDH1A1TSHRNPC1GRM5
SCHEMBL29530916 0.84 ALDH1A1 (0.63) ALDH1A1TSHRNPC1GRM5RAB9A
SCHEMBL30098987 0.84 ALDH1A1 (0.63) ALDH1A1TSHRNPC1GRM5RAB9A
SCHEMBL1711687 0.84 ALDH1A1 (0.63) ALDH1A1TSHRNPC1GRM5RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050197350-A1 Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof TAISHO PHARMACEUTICAL CO., LTD. 2005-09-08 US disclosed
EP-1464335-A2 Quinoline, tetrahydroquinoline and pyrimidine derivatives as mch antagonist Taisho Pharmaceutical Co. Ltd. (JP) 2004-10-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197350-A1 Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof HCRTR2, MCHR1, MCHR2 SMYD3 929/4885ALDH1A1 2036/4885TSHR 156/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.